Creative Planning’s Arcadia Biosciences RKDA Stock Holding History

Creative Planning’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-56	Closed	-$19K	–	1995
2017 Q3	$19K	Hold	56	–	–	﹤0.01%	1838
2017 Q2	$20K	Buy	56 +18	+47%	+$10K	﹤0.01%	3186
2017 Q1	$20K	Buy	+38	New	+$27.3K	﹤0.01%	3135

Other funds holding RKDA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Creative Planning's RKDA Position: Q4 2017 in Review

Creative Planning sold out of Arcadia Biosciences (RKDA) in Q4 2017, closing a stake of 56 shares — an estimated $19K sold.

Creative Planning first reported a position in RKDA in Q1 2017 and held it in 3 quarters. The position peaked at $20K in Q2 2017. 8 funds tracked by Wall St. Rank hold RKDA as of Q4 2017.

Creative Planning reported no remaining Arcadia Biosciences position as of Q4 2017 after selling out during the quarter.
Creative Planning sold 56 Arcadia Biosciences shares in Q4 2017, an estimated $19K.
Creative Planning first reported a position in Arcadia Biosciences in Q1 2017 and held it in 3 quarters.
Creative Planning's Arcadia Biosciences position peaked at $20K in Q2 2017.
8 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2017.

Based on Creative Planning's 13F filing for Q4 2017, filed 17 Jan 2018.